

Mãjrtã Pã©ntek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2220478/publications.pdf>

Version: 2024-02-01

130
papers

2,861
citations

159525

30
h-index

254106

43
g-index

148
all docs

148
docs citations

148
times ranked

3196
citing authors

#	ARTICLE	IF	CITATIONS
1	Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 399-408.	0.7	13
2	Measuring the acceptability of EQ-5D-3L health states for different ages: a new adaptive survey methodology. <i>European Journal of Health Economics</i> , 2022, 23, 1243-1255.	1.4	5
3	Validation of the PAM-13 instrument in the Hungarian general population 40 years old and above. <i>European Journal of Health Economics</i> , 2022, 23, 1341-1355.	1.4	7
4	Predicting Patient-Level 3-Level Version of EQ-5D Index Scores From a Large International Database Using Machine Learning and Regression Methods. <i>Value in Health</i> , 2022, 25, 1590-1601.	0.1	8
5	Comparing actuarial and subjective healthy life expectancy estimates: A cross-sectional survey among the general population in Hungary. <i>PLoS ONE</i> , 2022, 17, e0264708.	1.1	2
6	Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability. <i>Pharmacoeconomics</i> , 2022, 40, 587-599.	1.7	9
7	Patient-centred care in Hungary: Contributions to foster a policy agenda. <i>Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen</i> , 2022, , .	0.7	1
8	Disease burden of patients with pemphigus from a societal perspective. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 77-86.	0.7	9
9	Validation of the Hungarian version of the CarerQoL instrument in informal caregivers: results from a cross-sectional survey among the general population in Hungary. <i>Quality of Life Research</i> , 2021, 30, 629-641.	1.5	6
10	Subjective expectations regarding longevity and future health: a cross-sectional survey among patients with Crohn's disease. <i>Colorectal Disease</i> , 2021, 23, 105-113.	0.7	2
11	Self-Reported Waiting Times for Outpatient Health Care Services in Hungary: Results of a Cross-Sectional Survey on a National Representative Sample. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2213.	1.2	3
12	Outcomes of Digital Biomarker-Based Interventions: Protocol for a Systematic Review of Systematic Reviews. <i>JMIR Research Protocols</i> , 2021, 10, e28204.	0.5	17
13	EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1116-1123.	0.5	13
14	Comparing the measurement properties of the ICECAP-A and ICECAP-O instruments in ages 50-70: a cross-sectional study on a representative sample of the Hungarian general population. <i>European Journal of Health Economics</i> , 2021, 22, 1453-1466.	1.4	4
15	Editorial: Accelerated Globalization and Its Impact to the World's Health Care Achievement. <i>Frontiers in Public Health</i> , 2021, 9, 690239.	1.3	2
16	State of the Art in Adoption of Contact Tracing Apps and Recommendations Regarding Privacy Protection and Public Health: Systematic Review. <i>JMIR MHealth and UHealth</i> , 2021, 9, e23250.	1.8	48
17	Development of Population Tariffs for the ICECAP-A Instrument for Hungary and their Comparison With the UK Tariffs. <i>Value in Health</i> , 2021, 24, 1845-1852.	0.1	6
18	Costs of Infection Control and Special Challenges during the Covid-19 Pandemic: Experiences in a Military Hospital. <i>Academic and Applied Research in Military and Public</i> , 2021, 20, 95-110.	0.0	1

#	ARTICLE	IF	CITATIONS
19	Musculoskeletal health and capability wellbeing: Associations between the HAQ-DI, ICECAP-A and ICECAP-O measures in a population survey. <i>Musculoskeletal Science and Practice</i> , 2021, 55, 102420.	0.6	1
20	Assessment of cognitive function in female rheumatoid arthritis patients: associations with cerebrovascular pathology, depression and anxiety. <i>Rheumatology International</i> , 2020, 40, 529-540.	1.5	19
21	DLQI-R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea. <i>British Journal of Dermatology</i> , 2020, 182, 1167-1175.	1.4	25
22	Acceptable health and ageing: results of a cross-sectional study from Hungary. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 346.	1.0	3
23	Eliciting preferences for outpatient care experiences in Hungary: A discrete choice experiment with a national representative sample. <i>PLoS ONE</i> , 2020, 15, e0235165.	1.1	4
24	EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1423-1431.	0.5	11
25	Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. <i>Value in Health</i> , 2020, 23, 1235-1245.	0.1	58
26	Capability of well-being: validation of the Hungarian version of the ICECAP-A and ICECAP-O questionnaires and population normative data. <i>Quality of Life Research</i> , 2020, 29, 2863-2874.	1.5	13
27	Development of Population Tariffs for the CarerQoL Instrument for Hungary, Poland and Slovenia: A Discrete Choice Experiment Study to Measure the Burden of Informal Caregiving. <i>Pharmacoeconomics</i> , 2020, 38, 633-643.	1.7	6
28	Validity of EQ-5D-5L, Skindex-16, DLQI and DLQI-R in patients with hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2584-2592.	1.3	25
29	Dermatology Life Quality Index (DLQI) score bands are applicable to DLQI-Relevant (DLQI-R) scoring. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e484-e486.	1.3	7
30	Did You Get What You Wanted? Patient Satisfaction and Congruence Between Preferred and Perceived Roles in Medical Decision Making in a Hungarian National Survey. <i>Value in Health Regional Issues</i> , 2020, 22, 61-67.	0.5	8
31	Exploring eHealth Literacy and Patient-Reported Experiences With Outpatient Care in the Hungarian General Adult Population: Cross-Sectional Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e19013.	2.1	17
32	PNS32 Towards a Healthcare Cost Catalogue for Middle EAST and North Africa: A Systematic Review of Productivity Loss Costs Reported in Health Economic Publications between 1989-2019. <i>Value in Health</i> , 2020, 23, S649.	0.1	2
33	PNS38 Towards a Healthcare Cost Catalogue for Middle EAST and North Africa: A Systematic Review of Costs Reported in Health Economic Publications from Jordan, Lebanon Palestine and Syria 1995-2019. <i>Value in Health</i> , 2020, 23, S650.	0.1	1
34	PNS20 Towards a Healthcare Cost Catalogue for Middle EAST and North Africa: A Systematic Review of Costs Reported in Health Economic Publications from Egypt 1995-2019. <i>Value in Health</i> , 2020, 23, S647.	0.1	1
35	PNS19 Towards a Healthcare Cost Catalogue for Middle EAST and North Africa: A Systematic Review of Costs Reported in Health Economic Publications from Algeria, Libya, Morocco and Tunisia 1995-2019. <i>Value in Health</i> , 2020, 23, S647.	0.1	1
36	PNS34 Towards a Healthcare Cost Catalogue for Middle EAST and North Africa: A Systematic Review of Costs Reported in Health Economic Publications from the GULF Region 1995-2019. <i>Value in Health</i> , 2020, 23, S649.	0.1	1

#	ARTICLE	IF	CITATIONS
37	Patient experiences in a public primary health care clinic: A South African case study. <i>Society and Economy</i> , 2020, 42, 333-347.	0.2	2
38	Title is missing!. , 2020, 15, e0235165.		0
39	Title is missing!. , 2020, 15, e0235165.		0
40	Title is missing!. , 2020, 15, e0235165.		0
41	Title is missing!. , 2020, 15, e0235165.		0
42	Title is missing!. , 2020, 15, e0235165.		0
43	Title is missing!. , 2020, 15, e0235165.		0
44	Validity of the <sc>EQ</sc> â€”5D in patients with pemphigus vulgaris and pemphigus foliaceus. <i>British Journal of Dermatology</i> , 2019, 180, 802-809.	1.4	27
45	Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 537-549.	0.7	19
46	Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1472-1479.	0.5	7
47	Patientâ€”assigned health utility values for controlled and uncontrolled pemphigus vulgaris and foliaceus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2106-2113.	1.3	7
48	Determinants of the acceptability of health problems in different ages: exploring a new application of the EQ VAS. <i>European Journal of Health Economics</i> , 2019, 20, 31-41.	1.4	6
49	Psychometric properties of the Hungarian version of the eHealth Literacy Scale. <i>European Journal of Health Economics</i> , 2019, 20, 57-69.	1.4	49
50	Patient-reported outcomes: opportunities and challenges in Central Europe. <i>European Journal of Health Economics</i> , 2019, 20, 1-3.	1.4	2
51	The burden of informal caregiving in Hungary, Poland and Slovenia: results from national representative surveys. <i>European Journal of Health Economics</i> , 2019, 20, 5-16.	1.4	22
52	Unmet medical needs in ambulatory care in Hungary: forgone visits and medications from a representative population survey. <i>European Journal of Health Economics</i> , 2019, 20, 71-78.	1.4	17
53	Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies. <i>European Journal of Health Economics</i> , 2019, 20, 141-154.	1.4	12
54	Validity and reliability of the 9-item Shared Decision Making Questionnaire (SDM-Q-9) in a national survey in Hungary. <i>European Journal of Health Economics</i> , 2019, 20, 43-55.	1.4	25

#	ARTICLE	IF	CITATIONS
55	Patient experiences with outpatient care in Hungary: results of an online population survey. <i>European Journal of Health Economics</i> , 2019, 20, 79-90.	1.4	10
56	A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases. <i>European Journal of Health Economics</i> , 2019, 20, 119-132.	1.4	17
57	Subjective expectations regarding ageing: a cross-sectional online population survey in Hungary. <i>European Journal of Health Economics</i> , 2019, 20, 17-30.	1.4	11
58	Patient and general population values for luminal and perianal fistulising Crohn's disease health states. <i>European Journal of Health Economics</i> , 2019, 20, 91-100.	1.4	5
59	Cost-of-illness studies in nine Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2019, 20, 155-172.	1.4	23
60	Subjective well-being in patients with pemphigus: a path analysis. <i>European Journal of Health Economics</i> , 2019, 20, 101-107.	1.4	7
61	EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review. <i>European Journal of Health Economics</i> , 2019, 20, 109-117.	1.4	8
62	Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e267-e269.	1.3	19
63	PNS331 QUANTIFYING THE ACCEPTABILITY OF HEALTH PROBLEMS IN DIFFERENT AGES USING THE EQ-5D-3L INSTRUMENT. <i>Value in Health</i> , 2019, 22, S820.	0.1	1
64	PNS197 WAITING TIMES FOR HEALTH CARE SERVICES IN HUNGARY - RESULTS OF A REPRESENTATIVE POPULATION SURVEY. <i>Value in Health</i> , 2019, 22, S794.	0.1	2
65	Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease. <i>Quality of Life Research</i> , 2019, 28, 141-152.	1.5	41
66	Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis. <i>Advances in Therapy</i> , 2019, 36, 721-745.	1.3	7
67	Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. <i>Current Medicinal Chemistry</i> , 2019, 26, 259-269.	1.2	34
68	Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe. <i>United European Gastroenterology Journal</i> , 2018, 6, 310-321.	1.6	20
69	A detailed analysis of "not relevant" responses on the DLQI in psoriasis: potential biases in treatment decisions. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 783-790.	1.3	40
70	Is the DLQI appropriate for medical decision-making in psoriasis patients?. <i>Archives of Dermatological Research</i> , 2018, 310, 47-55.	1.1	24
71	PMS3 - INFliximab for Disease-Modifying Anti-Rheumatic Drug-Naïve Rheumatoid Arthritis Patients: Systematic Review and Descriptive Analysis of Publications of Randomized Controlled Trials. <i>Value in Health</i> , 2018, 21, S288.	0.1	1
72	Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis. <i>British Journal of Dermatology</i> , 2018, 179, 1102-1108.	1.4	42

#	ARTICLE	IF	CITATIONS
73	The Economic Impact of Biosimilars on Chronic Immune-Mediated Inflammatory Diseases. <i>Current Pharmaceutical Design</i> , 2018, 23, 6770-6778.	0.9	14
74	EQ-5D studies in cardiovascular diseases in eight Central and Eastern European countries: a systematic review of the literature. <i>Kardiologia Polska</i> , 2018, 76, 860-870.	0.3	19
75	Exploring the Relationship between Quality of Life (EQ-5D) and Clinical Measures in Adult Attention Deficit Hyperactivity Disorder (ADHD). <i>Applied Research in Quality of Life</i> , 2017, 12, 409-424.	1.4	4
76	Comparing self-perceived and estimated fracture risk by FRAX® of women with osteoporosis. <i>Archives of Osteoporosis</i> , 2017, 12, 4.	1.0	3
77	Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 126-132.	0.5	33
78	Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 597-606.	0.7	22
79	Assessment of skin involvement in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v53-v66.	0.9	41
80	EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis. <i>Rheumatology International</i> , 2017, 37, 1957-1977.	1.5	9
81	Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. <i>Quality of Life Research</i> , 2017, 26, 3409-3419.	1.5	51
82	Long-term costs and survival of prostate cancer: a population-based study. <i>International Urology and Nephrology</i> , 2017, 49, 1707-1714.	0.6	5
83	Bleeding out the quality-adjusted life years: evaluating the burden of primary dysmenorrhea using time trade-off and willingness-to-pay methods. <i>Pain</i> , 2017, 158, 2259-2267.	2.0	30
84	New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary. <i>Multiple Sclerosis Journal</i> , 2017, 23, 91-103.	1.4	13
85	Access to biologics in Crohn's disease in ten European countries. <i>World Journal of Gastroenterology</i> , 2017, 23, 6294.	1.4	35
86	Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 139-147.	0.7	15
87	Subjective health expectations of patients with age-related macular degeneration treated with anti-VEGF drugs. <i>BMC Geriatrics</i> , 2017, 17, 233.	1.1	17
88	Musculoskeletal Involvement in Systemic Sclerosis: An Unexplored Aspect of the Disease. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 19-32.	1.0	21
89	A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 1-7.	0.7	44
90	Alopecia areata and health-related quality of life: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2016, 175, 561-571.	1.4	144

#	ARTICLE	IF	CITATIONS
91	Valuation of pemphigus vulgaris and pemphigus foliaceus health states: a convenience sample experiment. <i>British Journal of Dermatology</i> , 2016, 175, 593-599.	1.4	15
92	Social/economic costs and health-related quality of life in patients with scleroderma in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 109-117.	1.4	28
93	Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 19-29.	1.4	59
94	Social/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 79-87.	1.4	40
95	Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 7-18.	1.4	38
96	Social/economic costs and health-related quality of life in patients with histiocytosis in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 67-78.	1.4	16
97	Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists. <i>Value in Health Regional Issues</i> , 2016, 10, 85-90.	0.5	11
98	EQ-5D in Central and Eastern Europe: 2000â€“2015. <i>Quality of Life Research</i> , 2016, 25, 2693-2710.	1.5	103
99	Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 89-98.	1.4	41
100	Patientsâ€™ access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 942-943.	0.5	21
101	Discrepancies between the Dermatology Life Quality Index and utility scores. <i>Quality of Life Research</i> , 2016, 25, 1687-1696.	1.5	16
102	Treatment preferences of originator versus biosimilar drugs in Crohnâ€™s disease; discrete choice experiment among gastroenterologists. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 22-27.	0.6	30
103	Use of biologics for psoriasis in Central and Eastern European countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2222-2230.	1.3	41
104	Health-related quality of life and its determinants in pemphigus: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2015, 173, 1076-1080.	1.4	24
105	Health Related Quality of Life in Patients with Bladder Cancer: A Cross-Sectional Survey and Validation Study of the Hungarian Version of the Bladder Cancer Index. <i>Pathology and Oncology Research</i> , 2015, 21, 619-627.	0.9	17
106	Biosimilars for the management of rheumatoid arthritis: economic considerations. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 43-52.	1.3	83
107	Moderate to severe psoriasis patients' subjective future expectations regarding health-related quality of life and longevity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1398-1405.	1.3	21
108	Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe. <i>World Journal of Gastroenterology</i> , 2015, 21, 1728.	1.4	64

#	ARTICLE	IF	CITATIONS
109	QUALITY OF LIFE OF PATIENTS WITH NON-DIABETIC PERIPHERAL NEUROPATHIC PAIN; RESULTS FROM A CROSS-SECTIONAL SURVEY IN GENERAL PRACTICES IN HUNGARY. <i>Ideggyogyaszati Szemle</i> , 2015, 68, 325-30.	0.4	2
110	Quality of Life and Costs in Parkinson's Disease: A Cross Sectional Study in Hungary. <i>PLoS ONE</i> , 2014, 9, e107704.	1.1	31
111	Subjective expectations regarding length and health-related quality of life in Hungary: results from an empirical investigation. <i>Health Expectations</i> , 2014, 17, 696-709.	1.1	24
112	Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists. <i>European Journal of Health Economics</i> , 2014, 15, 83-92.	1.4	20
113	Acceptability of less than perfect health states in rheumatoid arthritis: the patients' perspective. <i>European Journal of Health Economics</i> , 2014, 15, 73-82.	1.4	12
114	Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2014, 15, 35-43.	1.4	33
115	Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2014, 15, 27-34.	1.4	14
116	Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. <i>European Journal of Health Economics</i> , 2014, 15, 45-52.	1.4	27
117	Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. <i>European Journal of Health Economics</i> , 2014, 15, 53-64.	1.4	26
118	Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2014, 15, 65-71.	1.4	108
119	Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. <i>European Journal of Health Economics</i> , 2014, 15, 111-119.	1.4	60
120	HTA in Central and Eastern European countries; the 2001: A Space Odyssey and efficiency gain. <i>European Journal of Health Economics</i> , 2014, 15, 675-680.	1.4	7
121	Health economics and health technology assessment in Central and Eastern Europe: a dose of reality. <i>European Journal of Health Economics</i> , 2012, 13, 525-531.	1.4	27
122	Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study. <i>Health Policy</i> , 2012, 108, 19-26.	1.4	38
123	Health status and costs of ambulatory patients with multiple sclerosis in Hungary. <i>Ideggyogyaszati Szemle</i> , 2012, 65, 316-24.	0.4	7
124	Costs of dementia in Hungary. <i>Journal of Nutrition, Health and Aging</i> , 2010, 14, 633-639.	1.5	30
125	Cost-of-illness of patients with systemic sclerosis in a tertiary care centre. <i>Rheumatology</i> , 2010, 49, 1920-1928.	0.9	47
126	Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey. <i>Scandinavian Journal of Rheumatology</i> , 2010, 39, 303-309.	0.6	45

#	ARTICLE	IF	CITATIONS
127	History of health technology assessment in Hungary. International Journal of Technology Assessment in Health Care, 2009, 25, 120-126.	0.2	24
128	Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatology International, 2009, 30, 199-205.	1.5	36
129	Epidemiology of osteoporosis related fractures in Hungary from the nationwide health insurance database, 1999â€”2003. Osteoporosis International, 2008, 19, 243-249.	1.3	60
130	Costs of rheumatoid arthritis in Hungary. Journal of Rheumatology, 2007, 34, 1437.	1.0	27